Uçucu Maddeler: Tarihten Kliniğe
Özet
Uçucu maddeler (inhalanlar), duygusal ve zihinsel değişiklikler elde etmek amacıyla solunarak kötüye kullanılan, boya çözücüler, yapıştırıcılar, aerosoller, gazlar ve nitritler gibi yaygın endüstriyel ürünlerde bulunan geniş bir kimyasal grubudur. Kolay erişilebilir olmaları nedeniyle özellikle 9-14 yaş arası çocuk ve ergenlerde kullanımı yaygındır. Sosyoekonomik dezavantajlar, ailevi sorunlar ve adli süreç öyküsü gibi faktörler bu maddelere yönelimi artırmaktadır. Antik çağlardan beri dini ritüellerde zihin değişikliği için kullanılan bu maddeler, 19. yüzyıldan itibaren eğlence ve klinik anestezi amacıyla tüketilmeye başlanmıştır. Lipofilik özellikleri sayesinde kan-beyin bariyerini hızla geçen inhalanlar, merkezi sinir sistemindeki GABA ve NMDA gibi reseptörler üzerinden etki göstererek bağımlılık geliştirir. Düşük dozlarda neşelenme yaratırken yüksek dozlarda refleks kaybı, motor baskılanma, solunum depresyonu, kardiyak aritmi ve nörokognitif bozukluklar gibi ciddi sistemik hasarlara, hatta ani ölümlere yol açabilir. Tedavi süreçleri intoksikasyon yönetimi ve bağımlılık önlemeyi kapsar; bu noktada psikososyal müdahaleler, aile terapileri ve bilişsel davranışçı tedaviler ön plana çıkmaktadır. Yaygın sistemik hasarlar nedeniyle sadece psikiyatristlerin değil, tüm klinik disiplinlerin bu konuda farkındalık sahibi olması ve multidisipliner bir önleme stratejisinin geliştirilmesi büyük önem taşımaktadır.
Volatile substances (inhalants) are a broad group of chemicals found in common industrial products such as paint solvents, adhesives, aerosols, gases, and nitrites, which are abused by inhalation to achieve emotional and mental changes. Due to their easy accessibility, their use is prevalent especially among children and adolescents aged 9-14. Factors such as socioeconomic disadvantages, family problems, and a history of legal processes increase the tendency toward these substances. Used since ancient times in religious rituals for mind alteration, these substances began to be consumed for entertainment and clinical anesthesia purposes starting from the 19th century. Inhalants, which rapidly cross the blood-brain barrier thanks to their lipophilic properties, develop addiction by acting through receptors such as GABA and NMDA in the central nervous system. While they induce euphoria at low doses, high doses can cause severe systemic damage such as loss of reflexes, motor depression, respiratory depression, cardiac arrhythmia, and neurocognitive disorders, and even lead to sudden death. Treatment processes include intoxication management and addiction prevention; at this point, psychosocial interventions, family therapies, and cognitive behavioral treatments come to the forefront. Due to widespread systemic damage, it is of great importance for not only psychiatrists but all clinical disciplines to have awareness on this issue and to develop a multidisciplinary prevention strategy.
Referanslar
Sadock BJ. Kaplan & Sadock's synopsis of psychiatry: behavioral sciences/clinical psychiatry. 2007.
Balster RL, Cruz SL, Howard MO, et al. Classification of abused inhalants. Addiction. 2009;104(6): 878-882.
Yadav VK, Choudhary N, Heena Khan S, et al. Incense and Incense Sticks: Types, Components, Origin and Their Religious Beliefs and Importance among Different Religions. Journal of Bio Innovation. 2020;9: 1420-1439.
Paris JA. The Life of Sir Humphrey Davy: Colburn; 1831.
Marsh N, Marsh A. A short history of nitroglycerine and nitric oxide in pharmacology and physiology. Clinical and Experimental Pharmacology and Physiology. 2000;27(4): 313-319.
Young SJ, Longstaffe S, Tenenbein M. Inhalant abuse and the abuse of other drugs. The American journal of drug and alcohol abuse. 1999;25(2): 371-375.
Storr CL, Westergaard R, Anthony JC. Early onset inhalant use and risk for opiate initiation by young adulthood. Drug and alcohol dependence. 2005;78(3): 253-261.
Medina-Mora ME, Real T. Epidemiology of inhalant use. Current Opinion in Psychiatry. 2008;21(3): 247-251.
Johnston L, O'Malley PM, Bachman JG. National Survey Results on Drug Use from the Monitoring the Future Study, 1975-1998: Secondary school students: US Government Printing Office; 1999.
Beauvais F, Wayman JC, Jumper-Thurman P, et al. Inhalant abuse among American Indian, Mexican American, and non-Latino white adolescents. The American journal of drug and alcohol abuse. 2002;28(1): 171-187.
National Institute on Drug Abuse. Division of Epidemiology, Prevention Research, United States. Alcohol, Drug Abuse, Mental Health Administration. National household survey on drug abuse: Main findings: National Institute on Drug Abuse, Division of Epidemiology and Statistical; 2000.
Begin P, Weekes J, Thomas G. The Canadian Addiction Survey: Substance use and misuse among the Canadian population. In Forum on Corrections Research. Correctional Service Of Canada. 2006;18:12.
Burak M, Söyiler V, Pehlivan E. Adölesanlarda sigara içme ve madde kullanma prevalansı. Bağımlılık Dergisi. 2020;21(1): 64-71.
Williams JF, Storck M, Abuse CoS, et al. Inhalant abuse. Pediatrics. 2007;119(5): 1009-1017.
Sanchez ZM, Noto AR, Anthony JC. Social rank and inhalant drug use: the case of lança perfume use in São Paulo, Brazil. Drug and Alcohol Dependence. 2013;131(1-2): 92-99.
Schuckit M. Alkol ve Madde Kötüye Kullanımı. Kutlu Kamberoğlu (Ed.). İzmir : Kanyılmaz Matbaassı; 1993. p. 993.
Filley CM, Halliday W, Kleinschmidt-DeMasters B. The effects of toluene on the central nervous system. Journal of Neuropathology & Experimental Neurology. 2004;63(1): 1-12.
Chan M-H, Tang Y-C, Chien T-H, et al. Toluene exposure during the brain growth spurt reduced behavioral responses to nicotine in young adult rats: a potential role for nicotinic acetylcholine receptors in fetal solvent syndrome. Toxicological Sciences. 2008;101(2): 286-293.
Saracibar G, Hernandez ML, Echevarria E, et al. Toluene alters mu-opioid receptor expression in the rat brainstem. Industrial Health. 2001;39(3): 231-234.
Riegel AC, Zapata A, Shippenberg TS, et al. The abused inhalant toluene increases dopamine release in the nucleus accumbens by directly stimulating ventral tegmental area neurons. Neuropsychopharmacology. 2007;32(7): 1558-1569.
Bowen SE, Batis JC, Paez-Martinez N, et al. The last decade of solvent research in animal models of abuse: mechanistic and behavioral studies. Neurotoxicology and Teratology. 2006;28(6): 636-647.
Raines DE, Gioia F, Claycomb RJ, et al. The N-methyl-d-aspartate receptor inhibitory potencies of aromatic inhaled drugs of abuse: evidence for modulation by cation-π interactions. Journal of Pharmacology and Experimental Therapeutics. 2004;311(1): 14-21.
Brouette T, Anton R. Clinical review of inhalants. American Journal on Addictions. 2001;10(1): 79-94.
Cayir D, Demirel K, Korkmaz M, et al. Evaluation of lung epithelial permeability in the volatile substance abuse using Tc-99m DTPA aerosol scintigraphy. Annals of nuclear medicine. 2011;25(8): 554-559.
Dinsfriend W, Rao K, Matulevicius S. Inhalant-abuse myocarditis diagnosed by cardiac magnetic resonance. Texas Heart Institute Journal. 2016;43(3): 246-248.
Soderberg L, Flick J, Barnett J. Leukopenia and altered hematopoietic activity in mice exposed to the abused inhalant, isobutyl nitrite. Experimental Hematology. 1996;24(7): 848-853.
Taher SM, Anderson RJ, McCartney R, et al. Renal tubular acidosis associated with toluene “sniffing”. New England Journal of Medicine. 1974;290(14): 765-768.
Lubman D, Yücel M, Lawrence A. Inhalant abuse among adolescents: neurobiological considerations. British Journal of Pharmacology. 2008;154(2): 316-326.
Williams J. Committee on Substance Abuse, Committee on Native American Child Health. Inhalant abuse. Pediatrics. 2007;119: 1009-1017.
Ives R. Disorders relating to the use of volatile substance. In: Gelder MG, Lopez JJ, Andreasen NC (eds.) New Oxford Textbook of Psychiatry. 2000. p. 546-550.
Ridenour TA, Bray BC, Cottler LB. Reliability of use, abuse, and dependence of four types of inhalants in adolescents and young adults. Drug and Alcohol Dependence. 2007;91(1): 40-49.
Romanelli F, Smith KM, Thornton AC, et al. Poppers: epidemiology and clinical management of inhaled nitrite abuse. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2004;24(1): 69-78.
First MB. Diagnostic and statistical manual of mental disorders, and clinical utility. LWW; 2013: 727-729.
Kalayasiri R, Maes M. Addiction to, neurobiology of, and genetics of inhalants. Neuropathology of Drug Addictions and Substance Misuse: Elsevier; 2016. p. 958-63.
Lubke GH, Stephens SH, Lessem JM, et al. The CHRNA5/A3/B4 gene cluster and tobacco, alcohol, cannabis, inhalants and other substance use initiation: replication and new findings using mixture analyses. Behavior Genetics. 2012;42(4): 636-646.
Wu L-T, Howard MO. Psychiatric disorders in inhalant users: results from The National Epidemiologic Survey on Alcohol and Related Conditions. Drug and Alcohol Dependence. 2007;88(2-3): 146-155.
Wu L-T, Ringwalt CL. Inhalant use and disorders among adults in the United States. Drug and Alcohol Dependence. 2006;85(1): 1-11.
Sharp CW, Rosenberg N, Beauvais F. Substance Abuse: Inhalant‐Related Disorders. Psychiatry. 2008: 1127-1148.
Garland EL, Howard MO. Volatile substance misuse. CNS drugs. 2012;26(11): 927-935.
Misra LK, Fuller W. Treatment of inhalant abuse with risperidone. The Journal of Clinical Psychiatry. 1999;60(9): 881-887.
Erdoğan A, Yurteri N, editors. Aripiprazole treatment in the adolescent patients with inhalants use disorders and conduct disorder: a retrospective case analysis. Yeni symposium; 2010.
Lee DE, Schiffer WK, Dewey SL. Gamma-vinyl GABA (vigabatrin) blocks the expression of toluene-induced conditioned place preference (CPP). Synapse (New York, NY). 2004;54(3): 183-185.
MacLean S, Cameron J, Harney A, et al. Psychosocial therapeutic interventions for volatile substance use: a systematic review. Addiction. 2012;107(2): 278-288.
Ögel K, Coskun S. Cognitive behavioral therapy-based brief intervention for volatile substance misusers during adolescence: A follow-up study. Substance Use & Misuse. 2011;46: 128-133.
Liss B. Government, trade and industry and other preventative responses to volatile substance abuse. Human Toxicology. 1989;8(4): 327-330.
